Utility and safety of maintenance chemotherapy in advanced non–small cell lung cancer across various performance status categories: real-world experience
- 1 June 2020
- journal article
- review article
- Published by Elsevier in Current Problems in Cancer
- Vol. 44 (3) , 100565
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patientsWorld Journal of Clinical Oncology, 2018
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2017
- ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North IndiaAPMIS, 2016
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2015
- A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)Cancer Chemotherapy and Pharmacology, 2015
- Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?Journal of Clinical Oncology, 2013
- Management of advanced lung cancer in resource-constrained settings: a perspective from IndiaExpert Review of Anticancer Therapy, 2012
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trialLung Cancer, 2006